Abstracts tagged "giant cell arteritis"

Abstract Number: 805 • 2017 ACR/ARHP Annual Meeting
Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis
Andrea Gloor¹, Daniel Yerly², Stefan Kuchen³, Sabine Adler⁴, Stephan Reichenbach¹, Michael Seitz⁵ and Peter M. Villiger⁶, ¹Rheumatology, University hospital, Bern, Switzerland, ²Rheumatology, Uiversity hospital, Bern, Switzerland, ³Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland, ⁴Rheumatology, University Hospital Bern, Bern, Switzerland, ⁵Rheumatology, Clinical Immunology & Allergology, University Hospital, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) about tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
Abstract Number: 778 • 2017 ACR/ARHP Annual Meeting
Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations
Sara Gale¹, Sophie Dimonaco², Huong Trinh¹, Katie Tuckwell², Neil Collinson², John H. Stone³, Khaled Sarsour¹, Jinglan Pei⁴, Jennifer H. Best¹, Christine Birchwood⁴ and Shalini Mohan¹, ¹Genentech, South San Francisco, CA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Recent clinical trial findings have shown efficacy for tocilizumab (TCZ) in treating giant cell arteritis (GCA).1,2 TCZ was approved for the treatment of GCA…
Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting
Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Eishi Uechi and Kiyohide Fushimi, Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…
Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Martin Aringer³, Guido Hoese⁴, Wolfgang Ochs⁵, Katja Thiele¹ and Angela Zink^1,2, ¹Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ⁴Rheumatologische Fachpraxis Stadthagen, Stadthagen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany
Background/Purpose: Methods: Conclusion:
Abstract Number: 900 • 2016 ACR/ARHP Annual Meeting
The Phenotype of Macrophages in the Inflamed Vascular Wall of Giant Cell Arteritis Resembles the Phenotype of Non-Classical Monocytes
Yannick van Sleen, Qi Wang, Wayel H. Abdulahad, Arjan Diepstra, Annemieke M.H. Boots and Elisabeth Brouwer, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Macrophages are critical tissue destructive cells in the immunopathology of patients with giant cell arteritis (GCA). Macrophage precursors, monocytes, can be subclassified in three…
Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Luis Rodriguez Rodriguez¹, Leticia Leon², Inmaculada Morado¹, Zulema Rosales Rosado², Cristina Vadillo Font¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, Benjamín Fernández-Gutiérrez³, Juan A Jover Jover² and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…
Abstract Number: 856 • 2016 ACR/ARHP Annual Meeting
Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy
Lindsay Lally¹, Navneet Narula², Nicola Goodfellow³, Raashid Luqmani⁴ and Robert F. Spiera⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Pathology, Weill Cornell Medical College, New York, NY, ³Oxford, Oxofrd, United Kingdom, ⁴Oxford, Oxford, United Kingdom, ⁵Hospital for Special Surgery, Cornell, New York, NY
Background/Purpose: Aberrant rho-kinase (ROCK) activity is implicated in pathogenesis of several vascular and immunologic disorders. We previously demonstrated evidence of increased ROCK activity in histopathologically…
Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Bhaskar Dasgupta¹, Asad Khan¹, Dimos Merinopoulos¹, Siwalik Banerjee², Dawn Gayford³, Philip Stapleton¹, Faidra Laskou¹ and Gianina Statache¹, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Wescliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, westcliff-on-Sea, United Kingdom
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…
Abstract Number: 857 • 2016 ACR/ARHP Annual Meeting
Ultrasound Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis
Valentin S. Schäfer¹, Aaron Juche², Sofia Ramiro³, Andreas Krause² and Wolfgang A. Schmidt⁴, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Abstract Background/Purpose: Ultrasound (US) is increasingly used in the diagnosis of giant cell arteritis (GCA). US findings mainly rely on morphology (“halo-sign” and “compression sign”).…
Abstract Number: 977 • 2016 ACR/ARHP Annual Meeting
Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study
Maxime Samson¹, Hervé Devilliers², Kim Heang Ly³, Francois Maurier⁴, Boris Bienvenu⁵, Benjamin Terrier⁶, Pierre Charles⁷, Jean-François Besancenot², Anne-Laure Fauchais⁸, Christine Binquet⁹, Sylvain Audia¹⁰ and Bernard Bonnotte¹, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Internal Medicine, University Hospital of Limoges, Limoges, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Caen University Hospital, Caen, France, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁸Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁹INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis usually treated with glucocorticoids (GC). GC are effective but responsible for substantial morbidity and mortality. Tocilizumab…
Abstract Number: 861 • 2016 ACR/ARHP Annual Meeting
Efficacy of Methotrexate in Giant Cell Arteritis
Matthew J. Koster¹, Cynthia S. Crowson², Cristian Labarca³, Francesco Muratore⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ⁴Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Prospective trials evaluating methotrexate (MTX) as adjunct immunosuppression in giant cell arteritis (GCA) have provided evidence of a modest benefit for reducing risk of…
Abstract Number: 2074 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster and the Risk of Incident Giant Cell Arteritis
Bryant R. England¹, Ted R. Mikuls², Fenglong Xie³, Shuo Yang³, Lang Chen³ and Jeffrey Curtis⁴, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Antigenic triggers initiating granulomatous inflammation in giant cell arteritis (GCA) have yet to be elucidated. Recently, histopathological studies of temporal arteries from GCA patients…
Abstract Number: 862 • 2016 ACR/ARHP Annual Meeting
Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis
Sara Alehashemi¹, Mark Ahlman², Ali Cahid Civelek², Elaine Novakovich³, Ashkan Malayeri², Peter A. Merkel⁴, Thomas Cupps⁵, David Bluemke² and Peter C. Grayson³, ¹Rheumatology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ⁵Rheumatology, Georgetown University, Bethesda, MD
Background/Purpose: FDG-PET may have a role in diagnosing and monitoring disease activity in large vessel vasculitis (LVV). Studies that assess the diagnostic accuracy of PET…
Abstract Number: 2077 • 2016 ACR/ARHP Annual Meeting
Impact of Diabetes, Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Statin Use on Presentation and Outcomes in Patients with Giant Cell Arteritis
Jocelyn Ma^1,2, Nader A. Khalidi³, Ola Wierzbicki², Abdallah Al Qethami⁴, Simon Carette⁵ and Christian Pagnoux⁶, ¹Department of Family Medicine, University of Toronto, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ⁴Internal Medicine/Adult Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Few retrospective studies in giant cell arteritis (GCA) previously reported, separately, that 1) patients with diabetes had less positive temporal artery biopsies (TAB), 2)…
Abstract Number: 865 • 2016 ACR/ARHP Annual Meeting
Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis
Claire Le Pendu¹, Véronique Meignin², Solange Gonzalez-Chiappe³, Françoise Galateau-Sallé⁴ and Alfred Mahr³, ¹Internal Medicine, Hospital Saint Louis, PARIS, France, ²Pathology, Saint Louis Hospital, PARIS, France, ³Internal Medicine, Hospital Saint-Louis, Paris, France, ⁴Pathology, Caen Hospital, Caen, France
Background/Purpose: Histological findings of intima-media or transmural inflammation in temporal artery biopsies (TABs) have undisputed high value for diagnosis of giant cell arteritis (GCA). Conversely,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].